一种新的抗体Verekitug显示,呼吸道病人用一次剂量来进行长达24周的持久性炎症控制。 A new antibody, verekitug, shows lasting inflammation control for up to 24 weeks with one dose in respiratory patients.

上游生物组织提供了新数据,显示TSLP的受体瞄准抗体Verekitug在呼吸道病人一次剂量后可迅速、有力和持久地抑制发炎,最长持续24周。 Upstream Bio presented new data showing verekitug, a TSLP receptor-targeting antibody, provides rapid, strong, and lasting inhibition of inflammation for up to 24 weeks after a single dose in patients with respiratory conditions. 在对慢性犀牛皮炎和鼻涕虫的第二阶段试验中,Verekitug以每12周一次剂量达到关键端点,并获得良好许可。 In a Phase 2 trial for chronic rhinosinusitis with nasal polyps, verekitug met key endpoints with once-every-12-week dosing and was well-tolerated. 目前正在对严重哮喘和青蒿素综合症进行第二阶段试验,预计在2026年初取得头等成果。 Ongoing Phase 2 trials in severe asthma and COPD are underway, with top-line results expected in early 2026. 该药物的长期影响可能源于其高度亲近性结合以及TPLP受体的周转缓慢。 The drug’s long-lasting effects may stem from its high-affinity binding and the slow turnover of the TSLP receptor. 这是临床发育中唯一针对受体的TSLP抗体。 It is the only TSLP receptor-targeting antibody in clinical development.